Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 767-780

  De Stefano, Valerio ^a   Rossi, Elena ^a   Za, Tommaso ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antithrombotic prophylaxis; Hormonal treatment; Inherited thrombophilia; Pregnancy and puerperium; Surgery

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; HEPARIN; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN G20210A;

GENE SEGREGATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; ORAL CONTRACEPTION; PENETRANCE; PRIORITY JOURNAL; PUERPERIUM; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION DISORDERS, INHERITED; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PUERPERAL DISORDERS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 33845671758     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955459     Document Type: Review

References (144)

1. Jordan FLJ, Nandorff A. The familial tendency in thromboembolic disease. Acta Med Scand 1956;156:267-275
2. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-530
3. Griffin J, Evatt B, Zimmerman T, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373
4. Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984;311:1525-1528
5. Schwarz HP, Fischer M, Hopmeier P, Batard M, Griffin J. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-1300
6. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism: results of the Spanish multicentric study on thrombophilia. Thromb Haemost 1997;77:444-451
7. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-1231
8. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095-1108
9. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994;87:106-112
10. Beauchamp NJ, Dykes AC, Parikh N, Tait RC, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol 2004;125:647-654
11. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008
12. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506
13. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522
14. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
15. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
16. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998;24:367-379
17. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708
18. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolisnr. pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816
19. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877
20. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-176
21. De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000;26:305-311
22. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program) 2002:353-368
23. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol 2004;24:628-636
24. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173
25. Botto LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 2001;153:1016-1020
26. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 2003;72:636-649
27. Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003;5:261-268
28. Kelada SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ. The role of genetic polymorphisms in environmental health. Environ Health Perspect 2003;111:1055-1064
29. Khoury MJ, Yang Q, Gwinn M, Little J, Dana Flanders W. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med 2004;6:38-47
30. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004;20:640-647
31. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-1130
32. Clark P, Twaddle S, Walker ID, Scott L, Greer IA. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002;359:1919-1920
33. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-148
34. Recommendations of the European Society of Human Genetics. Provision of genetic services in Europe: current practices and issues. Eur J Hum Genet 2003;11(suppl 2): S2-S4
35. Recommendations of the European Society of Human Genetics. Population genetic screening programmes: technical, social and ethical issues. Eur J Hum Genet 2003; 11(suppl 2):S5-S7
36. Tosetto A, Frezzato M, Rodeghiero F. Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA Project. J Thromb Haemost 2003;1:1724-1729
37. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999;82:1395-1398
38. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996;76:824-834
39. Walker ID, Greaves M, Preston FE. Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512-528
40. Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001;98:21-22
41. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003;1:410-411
42. Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003;90:17-26
43. De Stefano V. Inherited thrombophilia and life-time risk of venous thromboembolism: is the burden reducible? J Thromb Haemost 2004;2:1522-1525
44. Pabinger I, Kyrie PA, Heistinger M, et al. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994;71:441-445
45. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999;94:3702-3706
46. Vossen CY, Conard J, Fontcuberta J, et al. Risk of first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005;3:459-464
47. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20
48. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002;99:1938-1942
49. Tirado I, Mateo J, Soria JM, et al. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica 2001;86:1200-1208
50. Martinelli I, Bucciarelli P, Margaglione M, et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-1229
51. Tormene D, Simioni P, Pagnan A, Prandoni P. The G20210A prothrombin gene mutation: is there room for screening families? J Thromb Haemost 2004;2:1487-1488
52. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation. A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004;164:1932-1937
53. Martinelli I, Bucciarelli P, Zighetti ML, Cafro A, Mannucci PM. Low risk of thrombosis in family members of patients with hyperhomocysteinaemia. Br J Haematol 2002;117:709-711
54. Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001;98:20
55. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003;1:412-413
56. Baglin T. Management of thrombophilia: who to screen? Pathophysiol Haemost Thromb 2003/2004;33:401-404
57. De Stefano V, Rossi E, Paciaroni K, et al. Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. Haematologica 2003;88:61-66
58. De Stefano V, Leone G, Mastrangelo S, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994;72:352-358
59. Spencer FA, Goldberg RJ. Asymptomatic thrombophilia-a family affair. J Thromb Haemost 2005;3:457-458
60. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987;58:1094
61. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-196
62. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-1188
63. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):627S-644S
64. Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512-528
65. Conard J, Horellou MH, Samama MM. Inherited thrombophilia and gestational venous thromboembolism. Semin Thromb Hemost 2003;29:131-142
66. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407
67. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003;1:1435-1442
68. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-1265
69. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999;54:265-271
70. Martinelli I, De Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87:791-795
71. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544
72. Abildgaard U, Viskjold F, Majak P. Hereditary antithrombin deficiency and pregnancy: venous thromboembolism despite prophylaxis with LMW heparin. Thromb Haemost 2001;(suppl): (abst P1470)
73. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982;14:127-141
74. De Stefano V, Leone G, De Carolis S, et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988;59:193-196
75. Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990;75:33-39
76. Wu O, Clark P, Lowe GDO, Walker ID, Greer IA. Thrombophilia and venous thromboembolism after total hip or knee replacement surgery: a systematic review. J Thromb Haemost 2005;3:811-813
77. Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee-a prospective study. Thromb Haemost 1999;81:18-21
78. Wahlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 2002;87:580-585
79. De Stefano V, Leone G, Mastrangelo S, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994;71:799-800
80. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):338S-400S
81. Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988;154:179-183
82. Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982;50:531-535
83. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003;43:390-394
84. Wuthrich RP. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens 2001; 10:409-414
85. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004;4:139-149
86. Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2001;72:549-550
87. Heidenreich S, Junker R, Wolters H, et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003;14:234-239
88. Ekberg H, Svensson PJ, Simanaitis M, Dahlbäck B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000;69:1577-1581
89. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with thrombophilia. Transplantation 1998;65:936-939
90. Friedman GS, Meier-Kriesche HU, Kaplan B, et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001;72:1073-1078
91. Martinelli I, Taioli E, Battaglioli T, et al. Risk of venous thromboembolism after air travel. Interaction with thrombophilia and oral contraceptives. Arch Intern Med 2003;163:2771-2774
92. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-783
93. Pérez-Rodriguez E, Jiménez D, Diàz G, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003;163:2766-2770
94. Otterson GA, Monahan BP, Harold N, et al. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996;101:406-412
95. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002;94:3120-3126
96. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-1599
97. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6
98. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722
99. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Medical progress: oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535
100. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. A clinical review. Arch Intern Med 2004;164:1965-1976
101. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004;27:1001-1018
102. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994;71:548-552
103. Wu O, Robertson L, Langhorne P, et al. Oral contra ceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thromb Haemost 2005;94:17-25
104. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
105. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596
106. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:28-31
107. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-703
108. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000;5:105-112
109. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 2001;86:965-971
110. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost 2004;2:430-436
111. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238
112. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-1797
113. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting factors. Arch Intern Med 2000;160:49-52
114. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-854
115. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a denned urban population. J Intern Med 1992;232:155-160
116. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):401S-428S
117. Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992;68:634-636
118. De Stefano V, Paciaroni K, Chiusolo P, et al. Treatment of acute thrombosis in patients with congenital antithrombin III deficiency. Thromb Haemost 1997;(suppl):433 (abst)
119. Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989;87(suppl 3B):53S-60S
120. Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S. International Committee on Thrombosis and Haemostasis. J Pediatr 1989;114:528-534
121. De Stefano V, Mastrangelo S, Schwarz HP, et al. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993;70:247-249
122. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical corse of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
123. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-774
124. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-526
125. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361
126. Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa? J Thromb Haemost 2003;1:16-18
127. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166:729-736
128. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-318
129. De Stefano V, Simioni P, Rossi E, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C, and protein S. Haematologica 2006;91:695-698
130. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005;25:1992-1997
131. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-806
132. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-1587
133. Nowak-Göttl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858-862
134. Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002;116:625-631
135. The Procare Group. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients? Blood Coagul Fibrinolysis 2003;14:523-529
136. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102-3110
137. Bauer KA. Management of thrombophilia. J Thromb Haemost 2003;1:1429-1434
138. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675-683
139. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004;351:268-277
140. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004;110(suppl 1)I-10-I-18
141. Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005;116:301-306
142. Finazzi G, Barbui T, for the ad hoc Study Group. A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. Res Clin Lab 1990;20:245-252
143. De Stefano V, Martinelli T, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006;135:386-391
144. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-969